STAT3-And STAT5-dependent pathways competitively regulate the pan-differentiation of CD34 pos cells into tumor-competent dendritic cells

Blood

Volumn 112, Issue 5, 2008, Pages 1832-1843

  Cohen, Peter A ^a,b   Koski, Gary K ^a,b   Czerniecki, Brian J ^c   Bunting, Kevin D ^b   Fu, Xin Yuan ^d   Wang, Zhengqi ^b   Zhang, Wen Jun ^d   Carter, Charles S ^e   Awad, Mohamed ^a   Distel, Christopher A ^a   Nagem, Hassan ^f   Paustian, Christopher C ^a   Johnson, Terrence D ^a   Tisdale, John F ^b   Shu, Suyu ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Department of Transfusion Medicine ^*

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CD34 ANTIGEN; INTERFERON REGULATORY FACTOR; INTERLEUKIN 12P70; INTERLEUKIN 6; STAT3 PROTEIN; STAT5 PROTEIN; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; FLT3 LIGAND PROTEIN; MEMBRANE PROTEIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STAT3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL POLARITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW CELL; C3H MOUSE; C57BL MOUSE; CYTOLOGY; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD34; BONE MARROW CELLS; CELL DIFFERENTIATION; DENDRITIC CELLS; FEMALE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-6; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR;

EID: 52649109063     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-12-130138     Document Type: Article

References (50)

1. Rosenberg SA, Yang JC, Restifo NR Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
2. Banchereau J, PaluckaAK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(×) progenitor-derived dendritic cell vaccine. Cancer Res. 2001; 61:6451-6458.
3. Bonifaz L, Bonnyay D, Mahnke K, et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histo-compatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med. 2002;196:1627-1638.
4. Xu S, Koski GK, Faries M, et al. Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12 dependent mechanism. J Immunol. 2003;171:2251-2261.
5. Berhanu A, Huang J, Alber SM, Watkins SC, Storkus WJ. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(×) T-cell cross-priming but is ineffective as a therapy. Cancer Res. 2006;66:4895-4903.
6. Czerniecki BJ, Koski GK, Koldovsky U, et al. Targeting HER2-neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007;67:1842-1852.
7. Napolitani G, Rinaldi A, Bertoni R Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol. 2005;6:769-776.
8. Czerniecki BJ. Carter C. Rivoltini L, et al. Calcium ionophore treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. J Immunol. 1997:159: 3823-3837.
9. Mailliard RB, Wankowicz-Kalinska A, Cai Q, et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004;64:5934-5937.
10. Gajewski TF, Renauld JC; Van Pel A, Boon T Co-stimulation with B7-1. IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J Immunol. 1995;154: 5637-5648.
11. Avigan D, Wu Z, Gong J, et al. Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-GSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation. Clin Cancer Res. 1999;5:2735-2741.
12. Pulendran B, Banchereau J, Burkeholder S, et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol. 2000;165:566-572.
13. Parajuli P, Mosley RL, Pisarev V, et al. Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets. Exp Hematol. 2001;29:1185-1193.
14. Kobie JJ, Wu RS, Kurt RA, et al. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res. 2003;63:1860-1864.
15. Gabrilovich D, IshidaT, OyarnaT et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92:4150-4166.
16. Yang AS. Lattime EC. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res. 2003;63:2150-2157.
17. Kalihski P, Schuitemaker JH, Hilkens CM, Kapsenberg ML. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83 + dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol. 1998; 161:2804-2809.
18. Ebihara Y. Tsuji K, Lyman SD, et al. Synergistic action of Flt3 and gp130 signalings in human hematopoiesis. Blood. 1997;90:4363-4368.
19. Sui X. Tsuji K, Tanaka R, et al. gp130 and c-Kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells. Proc Natl Acad Sci U S A. 1995:92:2859-2863.
20. Brasel K, McKenna HJ, Charrier K, et al. Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice. Blood. 1997;90:3781-3788.
21. high suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J Immunol. 2002;169:4811-4821.
22. Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHG class I and class II molecules. J Immunol. 2003;170:5317-5325.
23. Teglund S, McKay C, Schuetz E. et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 1998:93:841-850.
24. Cui Y, Riedlinger G, Miyoshi K, et al. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol. 2004;24:8037-8047.
25. Bunting KD, Bradley HL, HawleyTS, et al. Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood. 2002;99:479-487.
26. Welte T Zhang SS, Wang T et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci U S A. 2003; 100:1879-1884.
27. Kuriyama H, Shimizu K, Lee W, et al. Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells. Dev Biol (Basel). 2004;116:169-178.
28. Cohen PA, Cohen PJ, Rosenberg SA, Mule JJ. CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens. Cancer Res. 1994;54:1055-1058.
29. Peng L, Kjaergaard J, Weng DE, et al. Helper-independent CD8+/CD62L low T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression. J Immunol. 2000;165:5738-5749.
30. Tamura T, Tailor P, Yamaoka K, et al. I FN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity. J Immunol. 2005;174:2573-2581.
31. Onai N, Obata-Onai A, Tussiwand R, LanzavecchiaA, Manz MG. Activation of the Flt3 signal transduction cascade rescues and enhances type I interferon-producing and dendritic cell development. J Exp Med. 2006;203:227-238.
32. 8-fold hyperexpanded, CD4+ and CD8+ T cells. J Transl Med. (DOI 10.1186/1479-5876-2-41). 2004;2:4-1.
33. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med. 1996;184:1953-1962.
34. Brasel K, De SmedtT, Smith JL, Maliszewski CR. Generation of murine dendritic cells from flt. 3-ligand-supplemented bone marrow cultures. Blood. 2000;96:3029-3039.
35. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich Dl. Antigen-specific inhibition of CD8+ Tcell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol. 2004;172:989-999.
36. Serafini P, Carbley R, Noonan KA, et al. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004;64:6337-6343.
37. Iborra S, Abanades DR, Parody N, et al. The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers. Clin Exp Immunol. 2007;150:375-385.
38. Laouar Y, Welte T, Fu XY Flavell RA. STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity. 2003;19:903-912.
39. Majka M, Ratajczak J, Villaire G, et al. Thrombopoietin, but not cytokines binding to gp130 protein-coupled receptors, activates MAPKp42/44, AKT, and STAT proteins in normal human CD34+ cells, megakaryocytes, and platelets. Exp Hematol. 2002;30:751-760.
40. Lehtonen A, Matikainen S, Miettinen M, Julkunen I. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte/macrophage differentiation. J Leukoc Biol. 2002; 71:511-519.
41. Giron-Michel J, Fogli M. Gaggero A, et al. Detection of a functional hybrid receptor gammac/GM-CSFRbeta in human hematopoietic CD34+ cells. J Exp Med. 2003;197:763-775.
42. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11:1314-1321.
43. Chklovskaia E, Jansen W, Nissen C, et al. Mechanism of flt3 ligand expression in bone marrow failure: translocation from intracellular stores to the surface of T lymphocytes after chemotherapy-induced suppression of hematopoiesis. Blood. 1999;93:2595-2604.
44. Gaugler MH, Squiban C, Claraz M, et al. Characterization of the response of human bone marrow endothelial cells to in vitro irradiation. Br J Haematol. 1998;103:980-989.
45. Valladeau J, Duvert-Frances V, Pin JJ, etal. Immature human dendritic cells express asialoglycoprotein receptor isoforms for efficient receptormediated endocytosis. J Immunol. 2001;167: 5767-5774.
46. Cohen PA. Peng L, Plautz GE, et al. CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Grit Rev Immunol. 2000:20:17-56.
47. Oda S, Sato M, Toyoshima S, Osawa T Binding of activated macrophages to tumor cells through a macrophage lectin and its role in macrophage tumoricidal activity. J Biochem (Tokyo). 1989;105: 1040-1043.
48. Powell DJ Jr, Parker LL, Rosenberg SA. Largescale depletion of CD25+ regulatory T cells from patient leukapheresis samples. J Immunother. 2005;28:403-411.
49. Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004;114:280-290.
50. Mule JJ, Custer MC, Travis WD, Rosenberg SA. Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J Immunol. 1992;148:2622-2629.